📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-10 21:34
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
23 announcements match the current filters (relevance ≥ 5).
Supreme Court Dismisses ₹230.70 Cr GST Demand Case Against Aarti Drugs
The Supreme Court of India has dismissed a Special Leave Petition (SLP) filed by the GST Department against Aarti Drugs, concluding a long-standing tax dispute. The case originated from a show-cause notice proposing a demand of ₹230.70 Crores for the period FY 2017-18 to FY 2021-22. Following a favorable ruling from the Bombay High Court which set aside the demand, the Supreme Court's dismissal of the department's appeal provides finality to the matter. This resolution removes a significant contingent liability that was equivalent to approximately 120% of the company's TTM Net Profit.
Confidence: HIGH
What changedA major tax litigation involving a potential ₹230.70 Crore liability has been permanently resolved in the company's favor following the Supreme Court's dismissal of the GST Department's appeal.
Why it mattersThe resolution eliminates a significant financial risk; the disputed amount was larger than the company's entire annual profit (TTM PAT of ₹192 Cr), which could have severely impacted cash flows if ruled otherwise.
Total Disputed Amount: ₹230.70 CrDisputed Amount vs TTM PAT: 120.1%Disputed Amount vs Net Worth: 16.4%Specific Penalty Set Aside: ₹20.72 CrPeriod of Dispute: FY 2017-18 to FY 2021-22
📅 Short termPositive sentiment is expected as the company successfully defended a material tax claim, ensuring no unexpected cash outflows in the near term.
📈 Long termStructural positive as it clears the contingent liability profile, allowing management to focus on its backward integration and Greenfield expansion projects.
Key Highlights
Supreme Court dismissed the GST Department's appeal on August 10, 2026, in favor of the company.
The original dispute involved a proposed IGST demand of ₹230.70 Crores for the period FY 2017-18 to FY 2021-22.
The CGST authority had previously demanded a refund of ₹20.72 Crores and imposed a penalty of ₹20.72 Crores.
The total disputed amount of ₹230.70 Crores represents approximately 16.4% of the company's Net Worth (₹1405 Cr).
The company confirms there will be no financial or operational impact as the matter stands disposed of.
👀 What to Watch
Investors should note the removal of this legal overhang from the balance sheet. Focus can now return to the company's 15% growth strategy and the ramp-up of the Sayakha amines facility.
19% Revenue Growth in Q1 FY27; Sayakha Facility Hits 65% Utilization
Aarti Drugs reported a strong start to FY27 with consolidated revenue growing 19% YoY to ₹703.6 crore. EBITDA margins expanded by 120 bps to 13.8%, driven by improved API realizations and volume growth despite higher freight costs. The strategic Sayakha facility reached 65% utilization and is expected to meet 80-90% of captive intermediate requirements by Q3 FY27. Additionally, the company is doubling its oral solid dosage capacity at Baddi to scale its formulation exports, which already account for 74% of segment revenue.
Confidence: HIGH
What changedThe company has successfully stabilized operations at its new Sayakha plant and is transitioning from external intermediate procurement to captive production.
Why it mattersBackward integration through Sayakha is expected to add ~1% to gross margins at peak, while doubling formulation capacity targets higher-margin regulated export markets.
Q1 FY27 Revenue: ₹703.6 crRevenue vs TTM Revenue: 28.2%EBITDA Margin: 13.8%Sayakha Utilization: 65%Formulation Export Share: 74%Adjusted PAT Growth: 29%
📅 Short termThe stock may see positive sentiment following the margin expansion and the clear roadmap for backward integration benefits in the coming quarters.
📈 Long termStructural improvements through capacity doubling in formulations and cost leadership via backward integration could lead to a sustainable re-rating of the business.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Volatility in raw material prices (specifically ammonia derivatives)
- Elevated international freight costs
- Geopolitical risks impacting West Asian trade routes
Key Highlights
Consolidated revenue increased 19% YoY to ₹703.6 crore, representing approximately 28% of TTM revenue.
EBITDA grew 30% YoY to ₹96.9 crore, with margins expanding to 13.8% from 12.6% in the previous year.
Sayakha facility utilization reached 65%, with a target to reach 80-90% captive consumption by December 2026.
Formulation segment revenue stood at ₹81.6 crore, with 74% of this derived from export markets.
Baddi brownfield expansion is on track to nearly double the company's oral solid dosage manufacturing capacity.
👀 What to Watch
Monitor the EBITDA margin trajectory toward the management's 15-16% target as Sayakha utilization ramps up. Watch for the completion timeline of the Baddi expansion and any new USFDA/EDQM approvals for regulated market entry.
Aarti Drugs Q1 FY27: 19% Revenue Growth to ₹703.6 Cr; EBITDA Margins Expand to 13.8%
Aarti Drugs reported a strong operational start to FY27 with consolidated revenue growing 19% YoY to ₹703.6 Cr, driven by volume growth and a recovery in the pricing environment. EBITDA increased 30% YoY to ₹96.9 Cr, with margins expanding 120 bps to 13.8% due to product mix optimization and operational efficiencies. While PBT rose 35% YoY to ₹69.2 Cr, PAT declined 7% YoY to ₹50.1 Cr, primarily because the base quarter (Q1 FY26) included a one-time principal tax refund of ₹15 Cr. The Sayakha facility, a key backward integration project, reached ~65% utilization during the quarter.
Confidence: HIGH
What changedThe company has moved from a period of sharp API price erosion to a stabilizing pricing environment with consistent volume growth.
Why it mattersThe recovery in margins and the ramp-up of backward integration facilities (Sayakha) are critical for Aarti Drugs to maintain cost competitiveness against Chinese imports and improve operating leverage.
Q1 FY27 Revenue: ₹703.6 CrYoY Revenue Growth: 19%EBITDA Margin: 13.8%Sayakha Utilization: 65%Q1 FY27 PAT: ₹50.1 CrRevenue vs TTM Revenue: 28.2%
📅 Short termThe stock may react positively to the strong operational EBITDA growth and the stabilization of the pricing environment.
📈 Long termStructural growth is supported by capacity expansions in Baddi and Sayakha, alongside a strategic shift toward regulated markets and high-growth segments like GLP-1 intermediaries.
⚠ Risk flags
- Raw material price volatility
- Chinese oversupply/dumping risks
- High therapeutic concentration in Antibiotics (35%)
Key Highlights
Consolidated Revenue grew 19% YoY to ₹703.6 Cr, representing ~28% of TTM revenue.
EBITDA margins expanded by 120 bps YoY to 13.8%, nearing the management target of 15-16%.
Sayakha facility utilization reached ~65%, contributing to backward integration and margin support.
API segment continues to dominate, contributing 72.5% of total revenue for the quarter.
PBT grew 35% YoY to ₹69.2 Cr, despite a ₹2 Cr expense related to a CWIP write-off.
👀 What to Watch
Monitor the utilization ramp-up at the Sayakha facility and the execution timeline for the Baddi brownfield expansion, which aims to double oral solid dosage capacity. Investors should also track the management's ability to sustain the 15-16% EBITDA margin target amidst global raw material volatility.
19% Revenue Growth and 30% EBITDA Growth in Q1 FY27 for Aarti Drugs
Aarti Drugs reported a strong Q1 FY27 with consolidated revenue growing 19% YoY to ₹703.6 Cr, driven by volume growth and improved realizations. EBITDA increased 30% YoY to ₹96.9 Cr, with margins expanding by 120 bps to 13.8%. While reported PAT fell 7% to ₹50.1 Cr, this was due to a one-time ₹15 Cr tax refund in the base quarter; adjusted for this, PAT grew 29% YoY. The Specialty Chemicals segment was a standout, growing 150% YoY to ₹82.6 Cr.
Confidence: HIGH
What changedAarti Drugs has transitioned from a period of pricing pressure to a recovery phase with improved realizations and volume growth in Q1 FY27.
Why it mattersThe margin expansion and the ramp-up of the Sayakha facility (65% utilization) demonstrate the success of the company's backward integration strategy, which is critical for cost competitiveness in the API industry.
Q1 FY27 Revenue: ₹703.6 CrEBITDA Margin: 13.8%Specialty Chemicals Revenue: ₹82.6 CrSayakha Utilization: 65%Revenue vs TTM Revenue: 28.2%
📅 Short termThe stock may react positively to the operational beat and margin expansion, despite the optical decline in reported PAT.
📈 Long termStructural growth is supported by capacity doubling at Baddi and backward integration, though global raw material volatility remains a factor.
⚠ Risk flags
- Concentration in antibiotics (35% of API sales)
- Raw material price volatility
- Geopolitical risks impacting exports
Key Highlights
Consolidated Revenue grew 19% YoY to ₹703.6 Cr, representing ~28% of TTM revenue.
EBITDA increased 30% YoY to ₹96.9 Cr with margins expanding to 13.8%.
Specialty Chemicals segment revenue surged 150% YoY to ₹82.6 Cr.
Sayakha facility reached ~65% capacity utilization during the quarter.
Adjusted PAT grew 29% YoY when excluding a ₹15 Cr tax refund from Q1 FY26.
👀 What to Watch
Monitor the utilization levels at the Sayakha facility and the progress of the Baddi OSD expansion, which aims to double production capacity. Investors should also track if EBITDA margins can trend toward the management's long-term target of 15-16%.
₹10.2 Lakh Penalty Paid as GPCB Revokes Closure Order for Aarti Drugs' Sayakha Plant
The Gujarat Pollution Control Board (GPCB) has revoked a closure direction previously issued for Aarti Drugs' Amines manufacturing plant at Sayakha, Bharuch. The closure order followed an inspection on June 20, 2026, which identified non-compliances with the Water Act. To resume operations, the company paid an interim Environmental Damage Compensation (EDC) of ₹10.20 Lakhs. This facility is a critical component of the company's backward integration strategy, having been commissioned in September 2025.
Confidence: HIGH
What changedA regulatory threat to the operations of a key manufacturing facility has been resolved through the payment of a penalty and a revocation order from the GPCB.
Why it mattersThe Sayakha Amines facility is central to Aarti Drugs' strategy to improve cost competitiveness through backward integration; its continued operation is vital for maintaining API margins.
Interim Penalty (EDC): ₹10,20,000Penalty vs Net Worth: 0.007%Inspection Date: June 20, 2026Revocation Order Date: July 31, 2026
📅 Short termThe removal of the closure threat is a relief for the stock, ensuring no immediate loss of production at a newly commissioned facility.
📈 Long termWhile the financial penalty is negligible, the event underscores regulatory risks in the pharma-chemical sector; consistent ESG compliance is necessary to avoid future operational disruptions.
⚠ Risk flags
- Regulatory non-compliance
- Environmental litigation risk
- Potential for higher final compensation beyond the interim amount
Key Highlights
GPCB issued a revocation order on July 31, 2026, permitting the continuation of operations at the Sayakha plant.
Interim Environmental Damage Compensation (EDC) of ₹10,20,000 was levied under the 'Polluter Pays' principle.
The initial closure direction was based on an inspection conducted on June 20, 2026, citing Water Act non-compliances.
The Sayakha facility is a key backward integration project commissioned in September 2025 to support API margins.
Company confirms the interim penalty has already been deposited with the regulatory authority.
👀 What to Watch
Monitor the company's upcoming quarterly results to ensure the brief disruption at Sayakha did not impact production volumes or the 15-16% EBITDA margin target.
Aarti Drugs Announces Leadership Transition: Rashesh Gogri to Chairman, Adhish Patil to MD
Aarti Drugs has announced a structured leadership transition effective October 1, 2026. Shri Prakash M. Patil will retire as Chairman, MD, and CEO on September 30, 2026, after leading the company since 2014. Shri Rashesh C. Gogri (current MD) will be elevated to Chairman and MD, while Shri Adhish P. Patil (current CFO) will take over as Managing Director. This internal succession aims to maintain continuity as the company pursues its 15% growth target and backward integration projects.
Confidence: HIGH
What changedA formal succession plan has been activated where the long-standing Chairman/CEO is retiring, and the current MD and CFO are being promoted to lead the company.
Why it mattersInternal succession reduces execution risk during a period where the company is heavily investing in backward integration and capacity expansion to improve its 12% operating margins.
Transition Effective Date: October 1, 2026Total Manufacturing Facilities: 14Rashesh C. Gogri Experience: 27+ yearsAdhish P. Patil CFO Tenure: Since April 2014TTM Revenue: Rs 2492 Cr
📅 Short termThe market is likely to view this as a stable transition given both successors have been with the company for over a decade.
📈 Long termThe transition ensures continuity in the company's strategic shift toward backward integration and high-margin API segments like GLP-1 intermediaries.
⚠ Risk flags
- Vacancy in the CFO position following Adhish Patil's promotion
- Execution risk during leadership handover
Key Highlights
Shri Prakash M. Patil to retire from executive roles on September 30, 2026, after serving as Chairman since 2014.
Shri Rashesh C. Gogri, with 27+ years of industry experience, elevated to Chairman and MD effective October 1, 2026.
Shri Adhish P. Patil, CFO since April 2014, appointed as Managing Director effective October 1, 2026.
The company maintains 14 manufacturing facilities across Maharashtra, Gujarat, and Himachal Pradesh.
Transition occurs as the company targets a return to 15-16% EBITDA margins from the current 12% OPM.
👀 What to Watch
Investors should monitor the appointment of a new Chief Financial Officer to replace Adhish Patil and track the execution of the Sayakha amines facility and other greenfield projects under the new leadership.
Aarti Drugs Q1 FY27: Net Profit Surges 57% YoY to ₹55.3 Cr; Revenue Up 19%
Aarti Drugs reported a strong YoY performance for Q1 FY27, with consolidated revenue growing 19% to ₹702.78 Cr compared to ₹590.51 Cr in the year-ago quarter. Net profit surged 56.8% YoY to ₹55.26 Cr, maintaining stability sequentially despite a slight 2.4% dip in revenue from the March 2026 quarter. The company recorded a minor exceptional write-off of ₹2.09 Cr related to an administrative building. The results reflect the benefits of backward integration, particularly from the Sayakha amines facility commissioned in late 2025.
Confidence: HIGH
What changedAarti Drugs has reported its Q1 FY27 financial results, showing significant YoY growth in both top-line and bottom-line figures, alongside a routine exceptional write-off.
Why it mattersThe strong YoY profit growth indicates that the company's backward integration strategy is effectively offsetting raw material price volatility and domestic demand softness in antibiotics.
Consolidated Revenue (Q1 FY27): ₹702.78 CrConsolidated PAT (Q1 FY27): ₹55.26 CrYoY Revenue Growth: 19.0%YoY PAT Growth: 56.8%Exceptional Item (CWIP Write-off): ₹2.09 CrQ1 Revenue vs TTM Revenue: 28.2%
📅 Short termThe stock may react positively to the strong YoY profit jump and the fact that sequential earnings remained resilient despite a minor revenue dip.
📈 Long termStructural growth remains tied to the successful ramp-up of new capacities and the transition toward higher-margin products like GLP-1 intermediaries over the next 5-10 years.
⚠ Risk flags
- Soft domestic demand in the antibiotics category
- Susceptibility to raw material price fluctuations
- Rising finance costs
Key Highlights
Consolidated Revenue grew 19.0% YoY to ₹702.78 Cr from ₹590.51 Cr
Consolidated Net Profit increased 56.8% YoY to ₹55.26 Cr
Exceptional item of ₹2.09 Cr recorded for the write-off of CWIP for an administrative building
Quarterly EPS improved to ₹6.05 from ₹3.86 in the corresponding quarter last year
Finance costs rose to ₹9.22 Cr compared to ₹8.16 Cr in Q1 FY26
👀 What to Watch
Investors should monitor the company's ability to sustain EBITDA margins in the 15-16% range as the Sayakha facility ramps up. Key long-term triggers include the execution of the two Greenfield projects and progress in the GLP-1 anti-diabetic market entry.
Aarti Drugs Q1 FY27: Net Profit Jumps 67% YoY to ₹55.3 Cr; Revenue Up 19%
Aarti Drugs reported a strong year-on-year performance for Q1 FY27, with consolidated revenue growing 19% to ₹702.78 Cr compared to ₹590.51 Cr in the year-ago quarter. Net profit surged 67.4% YoY to ₹55.26 Cr, reflecting significant margin recovery from the previous year's base. Sequentially, the performance was stable, with revenue dipping slightly by 2.4% from Q4 FY26 while net profit remained flat. The company also recognized a minor exceptional write-off of ₹2.09 Cr related to administrative building construction.
Confidence: HIGH
What changedAarti Drugs released its audited Q1 FY27 results, showing a substantial year-on-year recovery in both top-line and bottom-line figures.
Why it mattersThe results indicate that the company is successfully navigating the pricing pressures in the API segment, with margins trending toward the management's long-term target of 15-16%.
Revenue (Q1 FY27): ₹702.78 CrNet Profit (Q1 FY27): ₹55.26 CrYoY Profit Growth: 67.4%EPS (Q1 FY27): ₹6.05Exceptional Write-off: ₹2.09 Cr
📅 Short termThe stock may see positive momentum as the 67% YoY profit growth exceeds the TTM growth trajectory and shows margin resilience.
📈 Long termLong-term value depends on the successful backward integration strategy and the potential entry into the GLP-1 market over the next 5-10 years.
⚠ Risk flags
- Susceptibility to raw material price fluctuations
- Soft domestic demand in the antibiotics category
Key Highlights
Consolidated Revenue grew 19% YoY to ₹702.78 Cr from ₹590.51 Cr.
Net Profit increased 67.4% YoY to ₹55.26 Cr compared to ₹33.0 Cr in Q1 FY26.
Calculated Operating Profit Margin improved to approximately 13.9% from the TTM average of 12.0%.
Exceptional item of ₹2.09 Cr write-off for Capital Work-in-Progress (CWIP) pertaining to an administrative building.
Earnings Per Share (EPS) for the quarter stood at ₹6.05, up from ₹3.62 in the year-ago period.
👀 What to Watch
Watch for management commentary on the utilization levels of the Sayakha amines facility and the execution timeline of the two ongoing Greenfield projects to sustain this margin recovery.
GPCB Orders Closure of Aarti Drugs' Saykha Amines Plant; 15-Day Grace Period for Compliance
Aarti Drugs has received a closure directive from the Gujarat Pollution Control Board (GPCB) for its Amines manufacturing facility at Saykha, Bharuch. The order, issued under Section 33A of the Water Act, follows an inspection on June 20, 2026, which identified non-compliance with environmental conditions. The closure is scheduled to take effect 15 days from July 18, 2026, unless the company successfully obtains a revocation. This facility is strategically significant as it was commissioned in September 2025 to drive backward integration and improve EBITDA margins toward the 15-16% target.
Confidence: HIGH
What changedThe Gujarat Pollution Control Board has mandated the shutdown of the company's Saykha Amines plant due to environmental non-compliance observed during a June 2026 inspection.
Why it mattersThe Saykha facility is a key component of the company's backward integration strategy, intended to reduce raw material costs and boost margins. A prolonged shutdown could delay the realization of these operational efficiencies and impact the TTM revenue of ₹2,492 Cr.
Inspection Date: June 20, 2026Notice Receipt Date: July 18, 2026Closure Grace Period: 15 daysTTM Revenue: ₹2,492 CrMarket Cap: ₹3,866 Cr
📅 Short termThe stock may face downward pressure in the coming days as the market reacts to the potential operational disruption at a key facility.
📈 Long termWhile the company is taking corrective steps, repeated environmental non-compliance can lead to increased regulatory scrutiny and may delay the company's goal of returning to 15-16% EBITDA margins.
⚠ Risk flags
- Regulatory non-compliance
- Operational disruption at a key backward integration facility
- Potential delay in margin improvement targets
Key Highlights
Closure order issued by GPCB under Section 33A of the Water (Prevention and Control of Pollution) Act, 1974.
Non-compliance identified during a regulatory inspection conducted on June 20, 2026.
Closure effective 15 days from the issuance of the letter dated July 18, 2026.
Affected unit is the Amines manufacturing plant at Plot No. DP-94 to DP-96, Saykha Industrial Estate.
Company is currently in the process of submitting corrective measures to obtain a revocation of the order.
👀 What to Watch
Investors should monitor the timeline for the company's submission of corrective measures and the subsequent response from GPCB regarding the revocation of the closure order.
Aarti Drugs Q4 FY26: Revenue Grows 6% YoY to ₹721.1 Cr; EBITDA Margins at 13.4%
Aarti Drugs reported a strong sequential recovery in Q4 FY26, with revenue rising 20% quarter-on-quarter to ₹721.1 crores. While PAT declined 12% year-on-year to ₹55.3 crores due to elevated input and energy costs, EBITDA margins stabilized at 13.4%. The company is transitioning from an investment phase to operational scale-up, with the new methylamine plant reaching 40% utilization and targeting 70% within a year. Notably, the contribution from regulated markets within exports increased to 73%, reflecting a shift toward higher-value products.
Key Highlights
Q4 FY26 revenue stood at ₹721.1 crores, up 6% YoY and 20% QoQ.
Formulation segment revenue surged 41% YoY to ₹91.3 crores, driven by export momentum.
Methylamine plant at Sayakha achieved 40% utilization in Q4, with a target of 55-60% for Q1 FY27.
Regulated market contribution to exports improved to 73% in FY26 from 66% in FY25.
Company targets 8-10% volume growth for FY27, supported by greenfield expansions and backward integration.
👀 What to Watch
Investors should focus on the successful ramp-up of the Sayakha facility and the potential margin expansion from backward integration. The increasing share of regulated markets and formulations suggests a structural improvement in the business mix despite short-term pricing volatility.
Aarti Drugs Q4 FY26: Revenue Up 6% to ₹721 Cr; PAT Declines 12% YoY Amid Margin Pressure
Aarti Drugs reported a steady 7% YoY revenue growth for FY26, reaching ₹2,568 crore, though Q4 FY26 PAT declined 12% YoY to ₹55.3 crore due to start-up losses at new facilities and domestic antibiotic market weakness. However, the company showed a strong sequential recovery in Q4, with EBITDA rising 72% QoQ and margins expanding by 410 bps to 13.4%. A key operational milestone was achieved at the Sayakha facility, reaching a run-rate of ~1,000 tonnes per month. The business mix is shifting favorably, with regulated market contribution rising to 73% and exports increasing to 38% of total revenue.
Key Highlights
Q4 FY26 Revenue grew 6% YoY to ₹721.1 crore, showing a strong 20% sequential recovery from Q3 FY26.
Full-year FY26 PAT increased 16% to ₹194.9 crore, despite pricing pressures in the API segment during the first half.
Sayakha facility reached a milestone production run-rate of ~1,000 tonnes per month in March 2026.
Contribution from regulated markets improved significantly to 73% in FY26 from 66% in FY25.
Specialty Chemicals and Formulations segments grew robustly by 37% and 33% YoY respectively.
👀 What to Watch
Investors should focus on the margin trajectory in FY27 as the Sayakha facility stabilizes and backward integration benefits materialize. While API pricing volatility remains a factor, the increasing share of regulated markets and exports provides a positive long-term outlook for earnings stability.
Aarti Drugs Q4 FY26: Revenue up 6% to ₹721 Cr; PAT falls 12% YoY but jumps 36% QoQ
Aarti Drugs reported a mixed Q4 FY26 with revenue growing 6% YoY to ₹721.1 crore, driven by strong performance in Formulations (+42%) and Specialty Chemicals (+46%). While YoY PAT declined by 12% to ₹55.3 crore due to start-up losses and antibiotic market weakness, the company saw a sharp 36% sequential recovery in PAT. The Sayakha facility reached a milestone run-rate of 1,000 tonnes per month in March 2026, signaling better operational efficiency ahead. Full-year FY26 PAT grew 16% to ₹194.9 crore, supported by an increased share of regulated markets which now contribute 73% of revenue.
Key Highlights
Consolidated FY26 revenue grew 7% YoY to ₹2,567.7 crore, while full-year PAT rose 16% to ₹194.9 crore.
Q4 FY26 EBITDA margins stood at 13.4%, reflecting a sharp recovery of 410 bps sequentially from Q3 FY26.
Formulations segment showed robust growth, increasing 42% YoY in Q4 to ₹92 crore.
Regulated market contribution improved significantly from 66% in FY25 to 73% in FY26.
The Sayakha facility achieved a production run-rate of ~1,000 tonnes per month in March 2026 despite ammonia shortages.
👀 What to Watch
Investors should monitor the margin trajectory as the Sayakha facility stabilizes and the domestic antibiotic market recovers. The increasing shift towards regulated markets and specialty chemicals provides a positive long-term outlook despite short-term pricing pressures in the API segment.
Aarti Drugs Reports FY26 Consolidated PAT Growth of 16% to ₹194.9 Crore
Aarti Drugs Limited delivered a steady financial performance for the fiscal year ended March 31, 2026, with consolidated revenue rising 9.9% year-on-year to ₹2,387 crore. The company's consolidated net profit for the full year grew by 16% to ₹194.9 crore, up from ₹168.1 crore in FY25. For the final quarter (Q4 FY26), revenue stood at ₹720.3 crore with a profit of ₹55.3 crore. Alongside the results, the board re-appointed its cost and internal auditors and expanded its Risk Management Committee.
Key Highlights
Consolidated Revenue for FY26 grew 9.9% YoY to ₹2,38,703 lakhs compared to ₹2,17,177 lakhs in FY25.
Full-year Consolidated Net Profit increased by 16% to ₹19,494 lakhs from ₹16,810 lakhs.
Basic EPS for the full year improved to ₹21.36 from ₹18.35 in the previous fiscal.
Q4 FY26 Consolidated Revenue rose 6.4% YoY to ₹72,030 lakhs.
Total Consolidated Assets increased to ₹2,81,526 lakhs as of March 31, 2026, from ₹2,57,468 lakhs a year ago.
👀 What to Watch
Investors should view the consistent double-digit profit growth and steady revenue expansion as a sign of operational stability. The stock remains a watch for those looking for steady growth in the pharmaceutical bulk drugs and chemicals space.
Aarti Drugs Q4 FY26 Net Profit Jumps 36% to ₹55.26 Cr; Full Year EPS Rises to ₹21.36
Aarti Drugs Limited reported a robust 36% year-on-year growth in consolidated net profit for Q4 FY26, reaching ₹55.26 crore. Consolidated revenue for the quarter rose 6.4% to ₹720.30 crore compared to the previous year. For the full financial year 2026, the company posted a net profit of ₹194.94 crore on a revenue of ₹2,387.03 crore, reflecting steady operational growth. The board also confirmed the re-appointment of internal and cost auditors and updated the Risk Management Committee.
Key Highlights
Consolidated Q4 net profit increased by 36.3% YoY to ₹55.26 crore from ₹40.54 crore.
Full-year FY26 consolidated revenue grew 8.9% to ₹2,387.03 crore compared to ₹2,191.62 crore in FY25.
Annual Earnings Per Share (EPS) improved to ₹21.36 in FY26 from ₹18.35 in the previous fiscal.
Consolidated Total Equity rose to ₹1,549.23 crore as of March 31, 2026, up from ₹1,369.34 crore in 2025.
Re-appointed M/s Raman S. Shah & Co. as Internal Auditors for a three-year term starting April 2026.
👀 What to Watch
The company demonstrates strong bottom-line growth and improving profitability margins; investors should maintain a positive outlook while monitoring raw material cost trends. Existing shareholders may hold as the steady EPS growth suggests healthy business fundamentals.
Aarti Drugs Faces Supreme Court Challenge from GST Dept Over ₹230.70 Cr Tax Dispute
The GST Department has filed a Special Leave Petition (SLP) in the Supreme Court challenging a Bombay High Court order that was previously in favor of Aarti Drugs. The dispute originates from a Show Cause Notice for FY 2017-18 to FY 2021-22 involving an IGST demand of ₹230.70 Crores. Although the High Court had earlier set aside the CGST authority's demand of ₹20.72 Crores plus penalties, the matter is now sub-judice at the highest court. This move reintroduces financial uncertainty regarding potential tax liabilities and penalties.
Key Highlights
GST Department files SLP in Supreme Court against the Bombay High Court's favorable order for the company.
Original dispute involves a total proposed IGST demand of ₹230.70 Crores for the period FY 2017-22.
Previous CGST order had confirmed a demand of ₹20.72 Crores and an equivalent penalty of ₹20.72 Crores.
The Bombay High Court had previously set aside the entire demand before this Supreme Court challenge.
Company states it is currently difficult to assess the exact financial impact as the matter is sub-judice.
👀 What to Watch
Investors should monitor the Supreme Court proceedings closely as a reversal of the High Court order could lead to significant cash outflows. No immediate action is required, but the legal risk premium on the stock may increase due to the size of the original claim.
Aarti Drugs to Invest ₹10 Crore in Subsidiary Pinnacle Life Science for Expansion
Aarti Drugs Limited has approved an investment of ₹10 crore in its wholly-owned subsidiary, Pinnacle Life Science Private Limited, through a rights issue. The capital infusion is specifically intended to finance Pinnacle's expansion and capital expenditure plans, alongside general corporate purposes. Pinnacle is a key formulations player for the group, exporting to over 30 countries, though its turnover saw a decline to ₹253.92 crore in FY25 from ₹314.66 crore in FY24. This investment signals the parent company's commitment to strengthening its formulations business segment.
Key Highlights
Investment of ₹10 crore via subscription to 78,125 equity shares at a price of ₹1,280 per share (including premium).
Pinnacle Life Science reported a turnover of ₹253.92 crore for FY 2024-25.
Funds will be utilized for financing expansion/capex plans and general corporate purposes.
Pinnacle operates in high-growth segments including oncology, cardiovascular, anti-infectives, and diabetics.
The share allotment is expected to be completed on or before March 20, 2026.
👀 What to Watch
Investors should view this as a strategic move to bolster the formulations subsidiary, though they should monitor if this capex helps reverse the recent decline in Pinnacle's annual turnover.
Aarti Drugs Q3 FY26: PAT Surges 58% to ₹40.5 Cr Despite EBITDA Margin Pressure
Aarti Drugs reported a mixed performance for Q3 FY26, with consolidated revenue growing 8% YoY to ₹602.9 crores and PAT surging 58% to ₹40.5 crores. However, EBITDA declined 10% YoY to ₹56.3 crores with margins contracting to 9.3% due to weak antibiotic demand, supply chain disruptions from China, and one-time plant shutdowns for refurbishment. The formulations segment was a bright spot, growing 58% YoY, driven by strong export demand. Management expects significant margin improvement as the new Sayakha facility ramps up from 30% to 50% utilization by April 2026.
Key Highlights
Consolidated revenue increased 8% YoY to ₹602.9 crores, while PAT rose 58% to ₹40.5 crores.
Formulations segment revenue grew 58% YoY to ₹76.6 crores, with exports accounting for 67% of segment sales.
The Sayakha greenfield facility achieved 30% utilization in its first quarter, targeting 50% by April 2026.
Operational headwinds including plant shutdowns and ramp-up costs impacted PBT by approximately ₹14-15 crores.
First oncology product commercialization is scheduled for Q4 FY26, with oncology expected to contribute 40% of formulation revenue in 3 years.
👀 What to Watch
Investors should focus on the successful ramp-up of the Sayakha facility and the commercialization of the oncology pipeline in Q4 as key triggers for margin recovery. While short-term margins are under pressure, the backward integration strategy is expected to add ₹50 crores to annual EBITDA at full scale.
Aarti Drugs Q3 FY26: PAT Jumps 58% YoY to ₹40.5 Cr; EBITDA Margins Contract to 9.3%
Aarti Drugs reported a mixed Q3 FY26 with revenue growing 8% YoY to ₹602.9 crore, led by strong growth in Formulations (+59%) and Specialty Chemicals (+51%). While PAT surged 58% YoY to ₹40.5 crore, operational EBITDA declined 10% YoY to ₹56.3 crore due to commissioning costs of new facilities and transient market dynamics. The company is aggressively pursuing backward integration, with its new Sayakha plant achieving 30% utilization and aiming for 100% self-reliance in Metformin intermediates within 8 months. Management indicates that pricing has reached an inflection point with improved momentum seen in January 2026.
Key Highlights
Consolidated Revenue grew 8% YoY to ₹602.9 crore, though API segment revenue slightly declined by 1% YoY.
EBITDA margins contracted by 190 bps YoY to 9.3% due to initial absorption of commissioning costs.
Formulations segment revenue rose 59% YoY to ₹76.4 crore, with exports accounting for 67% of this segment.
Sayakha plant for methyl amines achieved 30% capacity utilization in its first quarter of operations.
9M FY26 PAT stands at ₹139.7 crore, reflecting a 49% YoY growth compared to the previous year.
👀 What to Watch
Investors should monitor the capacity ramp-up at the Sayakha and Tarapur facilities, as successful backward integration is key to margin recovery. While the YoY PAT growth is strong, the QoQ decline in EBITDA suggests operational pressures that need to stabilize in the coming quarters.
Aarti Drugs Q3 FY26: Revenue Up 8% to ₹603 Cr, PAT Surges 58% Aided by Tax Refund
Aarti Drugs reported a steady 8% YoY revenue growth to ₹602.9 crore for Q3 FY26, driven by domestic demand and export formulations. While PAT surged 58% to ₹40.5 crore, this was significantly bolstered by a ₹16.38 crore income tax refund. Operational performance faced pressure as EBITDA fell 10% YoY to ₹56.3 crore, with margins contracting to 9.3% due to high-cost inventory consumption and temporary maintenance shutdowns. The company is making strategic progress in backward integration, with its new Sayakha facility reaching 30% capacity utilization in its first quarter.
Key Highlights
Consolidated revenue grew 8% YoY to ₹602.9 crore, while 9M FY26 revenue reached ₹1,846.6 crore.
EBITDA margins contracted by 190 bps YoY to 9.3% due to inventory-related factors and scheduled maintenance.
PAT increased 58% YoY to ₹40.5 crore, inclusive of a one-time IT tax refund of ₹16.38 crore.
Sayakha backward integration plant achieved 30% capacity utilization; expected to reach 50% by April 2026.
API segment continues to dominate the revenue mix at 75.5%, followed by Formulations at 12.7%.
👀 What to Watch
Investors should monitor the ramp-up of the Sayakha and Tarapur facilities, as successful backward integration is critical for margin recovery. While the PAT growth looks high, it is heavily influenced by a tax refund, so focus should remain on core EBITDA improvements in upcoming quarters.
Aarti Drugs Q3 Net Profit Rises 9.3% YoY to ₹40.55 Cr; Declares ₹2 Interim Dividend
Aarti Drugs reported a consolidated net profit of ₹40.55 crore for Q3 FY26, marking a 9.3% growth compared to ₹37.09 crore in the same period last year. Revenue from operations increased 8.1% YoY to ₹601.71 crore, although it saw a sequential decline from ₹652.79 crore in Q2. The company declared an interim dividend of ₹2 per share (20%) with a record date of February 9, 2026. Additionally, the company strengthened its leadership by inducting three functional heads into the Senior Management Personnel category to align with organizational growth.
Key Highlights
Consolidated Net Profit for Q3 FY26 stood at ₹40.55 crore, up from ₹37.09 crore YoY.
Revenue from operations grew 8.1% YoY to ₹601.71 crore for the quarter ended December 31, 2025.
Declared an interim dividend of ₹2 per equity share with a record date fixed for February 9, 2026.
9M FY26 consolidated net profit reached ₹140.54 crore on a total revenue of ₹1,845.01 crore.
New manufacturing plant at Sayakha, Gujarat, which commenced operations in Sept 2025, is now contributing to production.
👀 What to Watch
Investors may view the YoY growth and dividend declaration positively, though the sequential dip in revenue suggests monitoring margin pressures. Focus on the scaling of the new Sayakha plant as a primary growth catalyst for the upcoming quarters.
